Adler A

PSYCHOLOGY
Erasmus Medical Center
Greece

Doctor Pulmonology
Biography

Over the last 20 years, Dr. has gained wide-ranging experience in translating fundamental research into clinical development in various therapeutic areas, mainly in oncology and endocrinology. He is particularly experienced in the design and implementation of non-clinical development programs for small molecule drugs, targeted therapies, and biologics, as well as in the continued non-clinical evaluation of drug candidates supporting global registration.Over the last 20 years, Dr. has gained wide-ranging experience in translating fundamental research into clinical development in various therapeutic areas, mainly in oncology and endocrinology. He is particularly experienced in the design and implementation of non-clinical development programs for small molecule drugs, targeted therapies, and biologics, as well as in the continued non-clinical evaluation of drug candidates supporting global registration. Over the last 20 years, Dr. has gained wide-ranging experience in translating fundamental research into clinical development in various therapeutic areas, mainly in oncology and endocrinology. He is particularly experienced in the design and implementation of non-clinical development programs for small molecule drugs, targeted therapies, and biologics, as well as in the continued non-clinical evaluation of drug candidates supporting global registration.Over the last 20 years, Dr. has gained wide-ranging experience in translating fundamental research into clinical development in various therapeutic areas, mainly in oncology and endocrinology. He is particularly experienced in the design and implementation of non-clinical development programs for small molecule drugs, targeted therapies, and biologics, as well as in the continued non-clinical evaluation of drug candidates supporting global registration.

Research Intrest

Over the last 20 years, Dr. has gained wide-ranging experience in translating fundamental research into clinical development in various therapeutic areas, mainly in oncology and endocrinology. He is particularly experienced in the design and implementation of non-clinical development programs for small molecule drugs, targeted therapies, and biologics, as well as in the continued non-clinical evaluation of drug candidates supporting global registration.